Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495169 · ClinicalTrials.gov registry record · Phase 1
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
A Phase 1 study of Safety and Tolerability of Iloperidone, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 10
- Study locations
NCT01495169 is a Phase 1 study of Safety and Tolerability of Iloperidone that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 33 participants. The trial reports 10 study locations across 9 states.
The verdict
NCT01495169, a Phase 1 study of Safety and Tolerability of Iloperidone, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 10
- Study locations
Study Summary
Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication
Conditions Studied
Interventions
- DRUG iloperidone (oral tablet)
Study Locations (10)
Ohio
- Novartis Investigative Site - Cincinnati
- Novartis Investigative Site - Cleveland
California
- Novartis Investigative Site - Costa Mesa
Florida
- Novartis Investigative Site - North Miami
Georgia
- Novartis Investigative Site - Atlanta
Idaho
- Novartis Investigative Site - Coeur d'Alene
Maryland
- Novartis Investigative Site - Baltimore
Missouri
- Novartis Investigative Site - St Louis
New Jersey
- Novartis Investigative Site - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495169
The ClinicalTrials.gov registry entry for NCT01495169 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Safety and Tolerability of Iloperidone appearing as the primary indexed condition, and to 1 intervention - of which iloperidone (oral tablet) is the first listed.
NCT01495169 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01495169 about?
NCT01495169 is a clinical study titled "Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients". Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication
What is the current status of trial NCT01495169?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2011-10. Estimated completion is 2015-02.
What conditions does trial NCT01495169 study?
This clinical trial studies the following conditions: Safety and Tolerability of Iloperidone.
What interventions are being tested in trial NCT01495169?
The interventions under investigation include: iloperidone (oral tablet) (DRUG).
Who is sponsoring clinical trial NCT01495169?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01495169 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Idaho, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.